The effect of empagliflozin on circulating endothelial progenitor cells in patients with diabetes and stable coronary artery disease

被引:0
|
作者
Hershenson, Roy [1 ,2 ]
Nardi-Agmon, Inbar [1 ,2 ,3 ]
Leshem-Lev, Dorit [2 ,3 ]
Kornowski, Ran [1 ,2 ]
Eisen, Alon [1 ,2 ]
机构
[1] Rabin Med Ctr, Dept Cardiol, 39 Jabotinsky St, IL-49100 Petah Tiqwa, Israel
[2] Tel Aviv Univ, Fac Med, Tel Aviv, Israel
[3] Rabin Med Ctr, Felsenstein Med Res Ctr, Petah Tiqwa, Israel
关键词
Diabetes and cardiovascular disease; Endothelial progenitor cells; Cardioprotective effects of anti-diabetic medications; CARDIOVASCULAR OUTCOMES; MIGRATORY ACTIVITY; SGLT-2; INHIBITORS; PERIPHERAL-BLOOD; HEART-FAILURE; RISK-FACTORS; NUMBER; MECHANISMS; GLICLAZIDE; PROFILE;
D O I
10.1186/s12933-024-02466-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundDiabetes mellitus (DM) is associated with premature atherosclerotic disease, coronary artery disease (CAD) and chronic heart failure (HF), leading to increased morbidity and mortality. Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2i) exhibit cardioprotective benefits beyond glucose lowering, reducing the risk of major cardiovascular events (MACE) and HF hospitalizations in patients with DM and CAD. Endothelial progenitor cells (EPCs) are bone marrow-derived cells involved in vascular repair, mobilized in response to vascular injury. The number and function of circulating EPCs (cEPCs) are negatively affected by cardiovascular risk factors, including DM. This study aimed to examine the response of cEPCs to SGLT2i treatment in DM patients with stable CAD.MethodsA prospective single-center study included patients with DM and stable CAD who were started on an SGLT2i (empagliflozin). Peripheral blood samples were collected at baseline, 1 month, and 3 months to evaluate cEPC levels and function by flow cytometry, immunohistochemistry and MTT assays.ResultsEighteen patients were included in the study (median age 73, (IQR 69, 77) years, 67% male). After 1 month of treatment with empagliflozin, there was no significant change in cEPCs level or function. However, following 3 months of treatment, a significant increase was observed both in cell levels (CD34(+)/VEGFR-2(+): from 0.49% (IQR 0.32, 0.64) to 1.58% (IQR 0.93, 1.82), p = 0.0006; CD133(+)/VEGFR-2(+): from 0.38% (IQR 0.27, 0.6) to 0.82% (IQR 0.7, 1.95), p = 0.0001) and in cell function (from 0.25 CFUs (IQR 0, 0.5) at baseline, to 2 CFUs (IQR 1, 2) at 3 months, p = 0.0012).ConclusionsEmpagliflozin treatment in patients with DM and stable CAD increases cEPC levels and function, implying a cardioprotective mechanism. These findings highlight the potential of SGLT2i in treating cardiovascular diseases, warranting further research to explore these effects and their long-term implications.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Endothelial progenitor cells correlate with endothelial function in patients with coronary artery disease
    Nikos Werner
    Sven Wassmann
    Patrick Ahlers
    Tobias Schiegl
    Sonja Kosiol
    Andreas Link
    Katrin Walenta
    Georg Nickenig
    Basic Research in Cardiology, 2007, 102 : 565 - 571
  • [32] Circulating Progenitor Cells in Patients With Coronary Artery Disease and Renal Insufficiency
    Mehta, Anurag
    Tahhan, Ayman S.
    Liu, Chang
    Dhindsa, Devinder S.
    Nayak, Aditi
    Hooda, Ananya
    Moazzami, Kasra
    Islam, Shabatun J.
    Rogers, Steven C.
    Almuwaqqat, Zakaria
    Mokhtari, Ali
    Hesaroieh, Iraj
    Ko, Yi-An
    Waller, Edmund K.
    Quyyumi, Arshed A.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2020, 5 (08): : 770 - 782
  • [33] CIRCULATING ENDOTHELIAL PROGENITOR CELLS AND ENDOTHELIAL MICROPARTICLES IN HD PATIENTS WITH PERIPHERAL ARTERY DISEASE
    Seong, Lim Paik Alias Lin Po Sung
    Yin, Wu Ming
    Hsu, Chen Chang
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [34] Vascular progenitor cells in 500 patients with coronary artery disease:: Results of the Endothelial Progenitor Cells in Coronary Artery Disease (EPCAD) study
    Werner, N
    Ahlers, P
    Schiegl, T
    Kosiol, S
    Walenta, K
    Link, A
    Böhm, M
    Nickenig, G
    CIRCULATION, 2004, 110 (17) : 507 - 507
  • [35] Organic Nitrates Differentially Modulate Circulating Endothelial Progenitor Cells and Endothelial Function in Patients with Symptomatic Coronary Artery Disease
    Thum, Thomas
    Wiebking, Volker
    Ertl, Georg
    Bauersachs, Johann
    ANTIOXIDANTS & REDOX SIGNALING, 2011, 15 (04) : 925 - 931
  • [36] Circulating endothelial cells in coronary artery disease
    Lampka, Magdalena
    Grabczewska, Zofia
    Jendryczka-Mackiewicz, Ewa
    Holynska-Iwan, Iga
    Sukiennik, Adam
    Kubica, Jacek
    Halota, Waldemar
    Tyrakowski, Tomasz
    KARDIOLOGIA POLSKA, 2010, 68 (10) : 1100 - 1104
  • [37] Chronic pravastatin therapy increases outgrowth endothelial progenitor cells in patients with stable coronary artery disease
    Davani, S.
    Deschaseaux, F.
    Meneveau, N.
    Tiberghien, P.
    Kantelip, J. P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 : 27 - 27
  • [38] Chronic pravastatin therapy increases late endothelial progenitor cells in patients with stable coronary artery disease
    Deschaseaux, F.
    Meneveau, N.
    Kantelip, J. P.
    Davani, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 : 18 - 18
  • [39] Chronic pravastatin therapy increases outgrowth endothelial progenitor cells in patients with stable coronary artery disease
    Deschaseaux, Frederic
    Selmani, Zohair
    Meneveau, Nicolas
    Tiberghien, Pierre
    Kantelip, Jean-Pierre
    Bassand, Jean-Pierre
    Davani, Siamak
    CIRCULATION, 2006, 114 (18) : 52 - 52
  • [40] Expression of osteocalcin by circulating endothelial progenitor cells predicts endothelial dysfunction or structural coronary artery disease
    Moedde, U. I.
    Gossl, M.
    Lerman, A.
    Khosla, S.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S73 - S73